<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Trichomoniasis: Treatment
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Trichomoniasis: Treatment
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Trichomoniasis: Treatment
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Authors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Jack D Sobel, MD
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Caroline Mitchell, MD, MPH
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Robert L Barbieri, MD
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Jeanne Marrazzo, MD, MPH, FACP, FIDSA
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Kristen Eckler, MD, FACOG
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Nov 09, 2023.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H2689019312">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Trichomoniasis is a genitourinary infection with the protozoan
         <em>
          Trichomonas vaginalis
         </em>
         . It is the most common nonviral sexually transmitted infection (STI) worldwide. Females are affected more often than males. Trichomoniasis is one of the three common infectious causes of vaginal complaints among reproductive-aged females, along with bacterial vaginosis (BV) and candida vulvovaginitis, and is a cause of urethritis in males; however, the infection is often asymptomatic.
        </p>
        <p>
         The various clinical presentations of trichomoniasis and diagnostic tests are presented in related content. (See
         <a class="medical medical_review" href="/z/d/html/5453.html" rel="external">
          "Trichomoniasis: Clinical manifestations and diagnosis"
         </a>
         .)
        </p>
        <p>
         The approach to patients with vaginal discharge and urethritis are discussed separately.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/5477.html" rel="external">
          "Vaginitis in adults: Initial evaluation"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/86698.html" rel="external">
          "Urethritis in adult males"
         </a>
         .)
        </p>
        <p>
        </p>
        <p>
         In this topic, we use the terms "women" or "men" as they are used in the studies presented. We encourage the reader to consider the specific counseling and treatment needs of transgender and gender-expansive individuals.
        </p>
        <p class="headingAnchor" id="H1083185792">
         <span class="h1">
          WHOM TO TREAT
         </span>
         <span class="headingEndMark">
          —
         </span>
         Treatment is indicated for both symptomatic and asymptomatic persons with confirmed infection with
         <em>
          T. vaginalis
         </em>
         . Treatment has limited side effects, is associated with a high cure rate, likely reduces the prevalence of
         <em>
          T. vaginalis
         </em>
         carriage in the population, reduces transmission of the parasite, and reduces the risk of sequelae (including acquisition/transmission of HIV) [
         <a href="#rid1">
          1,2
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H1324080066">
         <span class="h1">
          5-NITROIMIDAZOLE DRUGS
         </span>
         <span class="headingEndMark">
          —
         </span>
         The 5-nitroimidazole drugs provide curative therapy of trichomoniasis.
        </p>
        <p class="headingAnchor" id="H3266016917">
         <span class="h2">
          Overall efficacy
         </span>
         <span class="headingEndMark">
          —
         </span>
         The 5-nitroimidazole drugs (
         <a class="drug drug_general" data-topicid="9646" href="/z/d/drug information/9646.html" rel="external">
          metronidazole
         </a>
         ,
         <a class="drug drug_general" data-topicid="10205" href="/z/d/drug information/10205.html" rel="external">
          tinidazole
         </a>
         , and
         <a class="drug drug_general" data-topicid="114899" href="/z/d/drug information/114899.html" rel="external">
          secnidazole
         </a>
         ) are the only class of drugs that provide curative therapy of trichomoniasis  (
         <a class="graphic graphic_algorithm graphicRef132757" href="/z/d/graphic/132757.html" rel="external">
          algorithm 1
         </a>
         ) [
         <a href="#rid3">
          3,4
         </a>
         ]. Most strains of
         <em>
          T. vaginalis
         </em>
         are highly susceptible to these agents [
         <a href="#rid5">
          5
         </a>
         ]. Randomized trials using these drugs have generally reported cure rates of 90 to 95 percent [
         <a href="#rid6">
          6-9
         </a>
         ]. Choice of agent is generally determined by availability, preference for single-day therapy, and cost. Management of nitroimidazole-resistant
         <em>
          Trichomonas
         </em>
         is discussed below. (See
         <a class="local">
          'Patients with persistent symptoms'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H3606508804">
         <span class="h2">
          Drugs and descriptions
         </span>
        </p>
        <p class="headingAnchor" id="H1733577797">
         <span class="h3">
          Metronidazole
         </span>
         <span class="headingEndMark">
          —
         </span>
         <a class="drug drug_general" data-topicid="9646" href="/z/d/drug information/9646.html" rel="external">
          Metronidazole
         </a>
         is available in oral and topical formulations and in single- and multi-dose regimens. Selection is determined by patient characteristics (eg, pregnant or not), patient preferences, and drug availability. (See
         <a class="local">
          'Treatment regimens'
         </a>
         below.)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Oral preferred to vaginal dosing
         </strong>
         – Cure rates for vaginal therapy with
         <a class="drug drug_general" data-topicid="9646" href="/z/d/drug information/9646.html" rel="external">
          metronidazole
         </a>
         gel are ≤50 percent, which is significantly lower than with oral therapy, and therefore therapy with topical metronidazole is not recommended [
         <a href="#rid1">
          1,10,11
         </a>
         ]. In a meta-analysis of two trials comparing oral versus vaginal metronidazole, use of oral metronidazole was 80 percent more likely to result in parasitological cure compared with vaginal therapy (risk ratio 0.20, 95% CI 0.07 to 0.56, n = 94) [
         <a href="#rid8">
          8
         </a>
         ]. Treatment with vaginal metronidazole gel does not reach therapeutic levels in the urethra and paravaginal glands, which serve as endogenous reservoirs of organisms that can cause disease recurrence.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Multi-dose compared with single-dose
         </strong>
         <a class="drug drug_general" data-topicid="9646" href="/z/d/drug information/9646.html" rel="external">
          metronidazole
         </a>
         <strong>
          therapy
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Data supporting multiday treatment for female patients
         </strong>
         – While single- (2 g) and multi-dose (500 mg twice daily for seven days) oral
         <a class="drug drug_general" data-topicid="9646" href="/z/d/drug information/9646.html" rel="external">
          metronidazole
         </a>
         treatment options are reasonable, multi-dose treatment is preferred based on studies in HIV-uninfected women reporting of higher cure rates following multi-dose treatment (multi-dose cure rates of 89 to 92 percent versus single-dose cure rates of 81 to 86 percent) [
         <a href="#rid6">
          6,12,13
         </a>
         ]. In a systematic review including five studies comparing multi-dose with single-dose therapy in women without HIV infection, single-day treatment was 80 percent more likely to be associated with treatment failure (pooled risk ratio of 1.80, 95% CI 1.07-3.02) [
         <a href="#rid13">
          13
         </a>
         ]. At least one study reported similar adherence for single- and multiday regimens (99 versus 96 percent, respectively) [
         <a href="#rid12">
          12
         </a>
         ]. Selection varies by the patient characteristics (eg, pregnant or not) and preferences. Either dosing regimen is associated with side effects (eg, nausea, vomiting, headache, metallic taste, dizziness); these effects appear to be dose-related and thus occur less frequently with the lower doses used in multi-dose therapy [
         <a href="#rid8">
          8,14
         </a>
         ]. The authors reserve single-dose therapy for female patients who are unable to complete a multi-dose treatment course of metronidazole.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Data supporting single-dose
         </strong>
         <a class="drug drug_general" data-topicid="9646" href="/z/d/drug information/9646.html" rel="external">
          metronidazole
         </a>
         <strong>
          treatment for male patients
         </strong>
         – Single-dose therapy for male patients is generally preferred because of ease of single dosing, although efficacy may be lower than that of multi-dose metronidazole therapy [
         <a href="#rid15">
          15,16
         </a>
         ]. However, trial data are limited. In a trial including 325 males comparing a single 2 g oral dose of metronidazole and metronidazole 400 mg three times daily for five days, treatment failure occurred in 43 percent of the single-dose patients and none of the multi-dose patients [
         <a href="#rid16">
          16
         </a>
         ]. Until data from an adequately powered trial are available, both dosing regimens are reasonable and patient preference, usually for single-dose treatment, determines treatment choice. The authors extrapolate this approach to individuals who have undergone surgical phalloplasty, although the authors are unaware of a reported case of trichomoniasis in a patient with phalloplasty.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3947091677">
         <span class="h3">
          Tinidazole
         </span>
         <span class="headingEndMark">
          —
         </span>
         <a class="drug drug_general" data-topicid="10205" href="/z/d/drug information/10205.html" rel="external">
          Tinidazole
         </a>
         , given as a single 2 g oral dose, is an alternative treatment for trichomonas infection for females and males [
         <a href="#rid1">
          1,17,18
         </a>
         ]. In addition, the World Health Organization (WHO) lists tinidazole 500 mg orally twice daily for five days as an alternative, although it is not clear which patients may benefit most from longer duration of initial treatment [
         <a href="#rid17">
          17
         </a>
         ]. In addition, the relative efficacy of either tinidazole dose compared with single- and multi-dose
         <a class="drug drug_general" data-topicid="9646" href="/z/d/drug information/9646.html" rel="external">
          metronidazole
         </a>
         is unclear. Although tinidazole was significantly more effective than metronidazole in several randomized trials including women, most of these trials were subject to bias since outcome was assessed by clinicians who were not blinded to the patient's treatment group [
         <a href="#rid8">
          8
         </a>
         ]. Data specific to male patients are limited. In one trial comparing oral tinidazole 1 g with oral metronidazole 1.5 g in 73 men with trichomoniasis, all had negative
         <em>
          T. vaginalis
         </em>
         cultures at 14 and 30 days post treatment [
         <a href="#rid19">
          19
         </a>
         ].
        </p>
        <p>
         Compared with
         <a class="drug drug_general" data-topicid="9646" href="/z/d/drug information/9646.html" rel="external">
          metronidazole
         </a>
         ,
         <a class="drug drug_general" data-topicid="10205" href="/z/d/drug information/10205.html" rel="external">
          tinidazole
         </a>
         generally causes fewer gastrointestinal side effects, but the cost may be higher and the drug may be less commercially available.
        </p>
        <p class="headingAnchor" id="H1872023778">
         <span class="h3">
          Secnidazole
         </span>
         <span class="headingEndMark">
          —
         </span>
         <a class="drug drug_general" data-topicid="114899" href="/z/d/drug information/114899.html" rel="external">
          Secnidazole
         </a>
         is a 5-nitroimidazole with a longer half-life (17 to 19 hours) than oral
         <a class="drug drug_general" data-topicid="9646" href="/z/d/drug information/9646.html" rel="external">
          metronidazole
         </a>
         (7 to 8 hours) and
         <a class="drug drug_general" data-topicid="10205" href="/z/d/drug information/10205.html" rel="external">
          tinidazole
         </a>
         (12 to 13 hours) [
         <a href="#rid20">
          20
         </a>
         ]. It is given as a single 2 g oral treatment for trichomoniasis [
         <a href="#rid21">
          21
         </a>
         ]. It is administered as a packet of granules which should be sprinkled onto a standard serving of applesauce, yogurt, or pudding and consumed within 30 minutes [
         <a href="#rid22">
          22
         </a>
         ]. Single-dose secnidazole is the only oral treatment option for both trichomoniasis and bacterial vaginosis (BV) in patients with a vagina [
         <a href="#rid23">
          23
         </a>
         ].
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Efficacy
         </strong>
         – Compared with placebo for treatment of trichomoniasis in females, cure rates of 92 percent were reported at 6- to 12-day follow-up, which is comparable to other 5-nitroimidazole single-dose regimens in this short-term follow-up period [
         <a href="#rid9">
          9,13
         </a>
         ]. Gastrointestinal side effects were reported in &lt;5 percent of participants in either arm, which is lower than rates reported with single-dose
         <a class="drug drug_general" data-topicid="9646" href="/z/d/drug information/9646.html" rel="external">
          metronidazole
         </a>
         [
         <a href="#rid12">
          12
         </a>
         ]. Data for using
         <a class="drug drug_general" data-topicid="114899" href="/z/d/drug information/114899.html" rel="external">
          secnidazole
         </a>
         in males with trichomoniasis are limited. In one trial comparing ornidazole, metronidazole, or secnidazole treatment in 85 men with confirmed trichomoniasis, all three treatment groups tested negative (by microscopic evaluation and culture of discharge) and were asymptomatic at follow-up evaluation [
         <a href="#rid24">
          24
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Limitations
         </strong>
         – While
         <a class="drug drug_general" data-topicid="114899" href="/z/d/drug information/114899.html" rel="external">
          secnidazole
         </a>
         may be preferred by patients for its single-day dosing, the cost may be higher because it is a newer treatment. Additionally, there are no head-to-head efficacy comparisons of single-dose secnidazole and the seven-day
         <a class="drug drug_general" data-topicid="9646" href="/z/d/drug information/9646.html" rel="external">
          metronidazole
         </a>
         regimen for the treatment of trichomoniasis in females or males.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1519809941">
         <span class="h2">
          Concerns with alcohol ingestion
         </span>
         <span class="headingEndMark">
          —
         </span>
         Previous guidelines and package label inserts have recommended avoiding alcohol ingestion while taking
         <a class="drug drug_general" data-topicid="9646" href="/z/d/drug information/9646.html" rel="external">
          metronidazole
         </a>
         due to a potential disulfiram-like reaction associated with 5-nitroimidazoles [
         <a href="#rid14">
          14
         </a>
         ]. However, several authors have reviewed the cases that are the basis of these reports and have not identified any convincing data to suggest that this is a true association [
         <a href="#rid25">
          25-28
         </a>
         ]. Disulfiram inhibits acetaldehyde dehydrogenase, leading to increased concentrations of acetaldehyde, while in vitro experiments show a decrease in acetaldehyde with addition of metronidazole [
         <a href="#rid29">
          29
         </a>
         ]. Thus, we do not believe that patients need to be counseled to avoid alcohol while using metronidazole and extrapolate this approach to
         <a class="drug drug_general" data-topicid="10205" href="/z/d/drug information/10205.html" rel="external">
          tinidazole
         </a>
         and
         <a class="drug drug_general" data-topicid="114899" href="/z/d/drug information/114899.html" rel="external">
          secnidazole
         </a>
         .
        </p>
        <p class="headingAnchor" id="H4087857324">
         <span class="h1">
          TREATMENT REGIMENS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Treatment is indicated in all persons diagnosed with trichomoniasis, even if asymptomatic, and their sex partners  (
         <a class="graphic graphic_algorithm graphicRef132757" href="/z/d/graphic/132757.html" rel="external">
          algorithm 1
         </a>
         ). We use the regimens below, which are in agreement with the World Health Organization (WHO) and/or the US Centers for Disease Control and Prevention (CDC), except as noted [
         <a href="#rid1">
          1,17
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H600149019">
         <span class="h2">
          Females
         </span>
        </p>
        <p class="headingAnchor" id="H2416505632">
         <span class="h3">
          Nonpregnant
         </span>
         <span class="headingEndMark">
          —
         </span>
         Nonpregnant females are preferentially treated with a multi-dose oral
         <a class="drug drug_general" data-topicid="9646" href="/z/d/drug information/9646.html" rel="external">
          metronidazole
         </a>
         regimen rather than single-day treatment because multi-dose therapy is associated with improved cure rates at one month [
         <a href="#rid12">
          12,13
         </a>
         ].
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Preferred
         </strong>
         –
         <a class="drug drug_general" data-topicid="9646" href="/z/d/drug information/9646.html" rel="external">
          Metronidazole
         </a>
         500 mg, tablet or capsule, orally twice daily for seven days [
         <a href="#rid1">
          1,17,18,30-32
         </a>
         ]. The authors prefer this approach because of higher efficacy compared with single-day regimens [
         <a href="#rid12">
          12,13
         </a>
         ]. An oral suspension is also available with unique dosing (metronidazole oral suspension 250 mg [2.5 mL] orally three times daily for seven days) [
         <a href="#rid33">
          33
         </a>
         ]. (See
         <a class="local">
          'Metronidazole'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Alternatives
         </strong>
         –
         <strong>
         </strong>
         Alternative treatments vary according to the source guideline (CDC compared with WHO). As direct comparative data are lacking, selection is based on availability and cost.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Single-dose options
         </strong>
         – Treatment with a single 2 g oral dose of either
         <a class="drug drug_general" data-topicid="9646" href="/z/d/drug information/9646.html" rel="external">
          metronidazole
         </a>
         or
         <a class="drug drug_general" data-topicid="10205" href="/z/d/drug information/10205.html" rel="external">
          tinidazole
         </a>
         (ie, four 500 mg tablets) is associated with lower rates of cure compared with metronidazole multi-dose therapy [
         <a href="#rid1">
          1,8
         </a>
         ].
         <strong>
         </strong>
         The authors reserve single-dose therapy for those who are unable to complete a multi-dose treatment course.
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         <a class="drug drug_general" data-topicid="9646" href="/z/d/drug information/9646.html" rel="external">
          Metronidazole
         </a>
         2 g orally given as a single dose [
         <a href="#rid17">
          17
         </a>
         ] or metronidazole oral suspension 2 g (20 mL), either as a single oral dose or in two divided oral doses of 1 g (10 mL) each, given on the same day [
         <a href="#rid33">
          33
         </a>
         ]. (See
         <a class="local">
          'Metronidazole'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         OR
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         <a class="drug drug_general" data-topicid="10205" href="/z/d/drug information/10205.html" rel="external">
          Tinidazole
         </a>
         2 g orally given as a single dose [
         <a href="#rid1">
          1,18
         </a>
         ]. (See
         <a class="local">
          'Tinidazole'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         OR
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         <a class="drug drug_general" data-topicid="114899" href="/z/d/drug information/114899.html" rel="external">
          Secnidazole
         </a>
         2 g orally given as a single dose [
         <a href="#rid9">
          9,34
         </a>
         ] (single-dose secnidazole is effective treatment for both trichomoniasis and bacterial vaginosis). (See
         <a class="local">
          'Secnidazole'
         </a>
         above and
         <a class="medical medical_review" href="/z/d/html/113103.html" rel="external">
          "Bacterial vaginosis: Initial treatment", section on 'Secnidazole'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Multi-dose
         </strong>
         <a class="drug drug_general" data-topicid="10205" href="/z/d/drug information/10205.html" rel="external">
          tinidazole
         </a>
         – Tinidazole 500 mg orally twice daily for five days is an alternative option listed by WHO [
         <a href="#rid17">
          17
         </a>
         ]. It is not yet known which patient groups may benefit from multi-dose tinidazole compared with single-dose for initial treatment. We reserve multi-dose tinidazole for patients with persistent infection despite adequate initial treatment and use a higher dose in this setting (tinidazole 2 g daily for seven days [
         <a href="#rid1">
          1
         </a>
         ]). (See
         <a class="local">
          'Treatment'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Not advised
         </strong>
         – Vaginal
         <a class="drug drug_general" data-topicid="9646" href="/z/d/drug information/9646.html" rel="external">
          metronidazole
         </a>
         gel is not recommended because it does not effectively treat all anatomic reservoirs of infection and should not be used to treat trichomoniasis [
         <a href="#rid1">
          1
         </a>
         ]. However, metronidazole vaginal gel remains on at least one treatment guideline [
         <a href="#rid17">
          17
         </a>
         ]. (See
         <a class="local">
          'Metronidazole'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H375896459">
         <span class="h3">
          Pregnant
         </span>
         <span class="headingEndMark">
          —
         </span>
         Treatment of pregnant persons, with or without symptoms, is indicated as
         <em>
          T. vaginalis
         </em>
         infection is common in pregnant persons and has been associated with adverse pregnancy outcomes [
         <a href="#rid1">
          1,35,36
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/5453.html" rel="external">
          "Trichomoniasis: Clinical manifestations and diagnosis", section on 'Female'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1124348170">
         <span class="h4">
          Treatment and dosing options
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Preferred
         </strong>
         –
         <a class="drug drug_general" data-topicid="9646" href="/z/d/drug information/9646.html" rel="external">
          Metronidazole
         </a>
         500 mg orally twice daily for seven days, regardless of trimester [
         <a href="#rid1">
          1,17
         </a>
         ]. An oral suspension is also available (metronidazole oral suspension 250 mg [2.5 mL] orally three times daily for seven days) [
         <a href="#rid33">
          33
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         This is our preferred regimen as we believe the available evidence supports the benefits of treatment, including reduced partner and perinatal transmission, and outweighs potential risks, although at least one organization advises waiting until after the first trimester for treatment, if possible [
         <a href="#rid17">
          17
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Alternate regimens
         </strong>
         –
         <strong>
         </strong>
         WHO lists the following as alternative treatment options with the notation to avoid
         <a class="drug drug_general" data-topicid="9646" href="/z/d/drug information/9646.html" rel="external">
          metronidazole
         </a>
         use in the first trimester of pregnancy if possible [
         <a href="#rid17">
          17
         </a>
         ]. While data directly comparing the treatment options in pregnant persons are lacking, there is no reason to think that pregnancy would make the alternative regimens more effective than multi-dose oral metronidazole.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <a class="drug drug_general" data-topicid="9646" href="/z/d/drug information/9646.html" rel="external">
          Metronidazole
         </a>
         2 g orally in a single dose [
         <a href="#rid17">
          17
         </a>
         ]. An oral suspension is also available (metronidazole oral suspension 2 g [20 mL], either as a single oral dose or in two divided oral doses of 1 g [10 mL] each, given on the same day) [
         <a href="#rid33">
          33
         </a>
         ]. While single-day dosing is included as a first-line treatment option in the WHO sexually transmitted infection (STI) treatment guidelines, we view it as an alternative for the reasons discussed above. However, both single- and multiple-dose regimens are acceptable as there are no specific data comparing single-dose and multiple-dose regimens in pregnant individuals and there are no reasons to think that efficacy is different in pregnant patients. In our practices, we reserve the single-dose regimen for pregnant individuals who are unable to complete seven days of treatment or prefer single-dose therapy.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         OR
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <a class="drug drug_general" data-topicid="9646" href="/z/d/drug information/9646.html" rel="external">
          Metronidazole
         </a>
         200 or 250 mg orally three times daily for seven days [
         <a href="#rid17">
          17
         </a>
         ]. These doses may not be universally available.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Not advised during pregnancy
         </strong>
         – In our practices, we do not use
         <a class="drug drug_general" data-topicid="9646" href="/z/d/drug information/9646.html" rel="external">
          metronidazole
         </a>
         gel,
         <a class="drug drug_general" data-topicid="10205" href="/z/d/drug information/10205.html" rel="external">
          tinidazole
         </a>
         , or
         <a class="drug drug_general" data-topicid="114899" href="/z/d/drug information/114899.html" rel="external">
          secnidazole
         </a>
         in pregnant persons.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <a class="drug drug_general" data-topicid="9646" href="/z/d/drug information/9646.html" rel="external">
          Metronidazole
         </a>
         vaginal gel does not effectively treat all anatomic reservoirs of infection and is not advised [
         <a href="#rid1">
          1
         </a>
         ], although at least one guideline lists metronidazole gel as a third-line treatment option [
         <a href="#rid17">
          17
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <a class="drug drug_general" data-topicid="10205" href="/z/d/drug information/10205.html" rel="external">
          Tinidazole
         </a>
         and
         <a class="drug drug_general" data-topicid="114899" href="/z/d/drug information/114899.html" rel="external">
          secnidazole
         </a>
         – We avoid oral tinidazole or secnidazole, especially in the first trimester, as safety data from human pregnancies are insufficient to make a definitive conclusion regarding teratogenicity and some, but not all, animal data suggest risk [
         <a href="#rid1">
          1,21,23,37,38
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H834424286">
         <span class="h4">
          Teratogenicity
         </span>
         <span class="headingEndMark">
          —
         </span>
         While
         <a class="drug drug_general" data-topicid="9646" href="/z/d/drug information/9646.html" rel="external">
          metronidazole
         </a>
         crosses the placenta [
         <a href="#rid39">
          39
         </a>
         ], it appears to be low risk to the developing fetus. Cross-sectional and cohort studies have not reported teratogenicity or mutagenic effects for single- or multi-dose metronidazole treatment in humans (although studies suggest the drug is mutagenic in bacteria and carcinogenic in mice) [
         <a href="#rid40">
          40-44
         </a>
         ]. There is limited information on the safety of
         <a class="drug drug_general" data-topicid="10205" href="/z/d/drug information/10205.html" rel="external">
          tinidazole
         </a>
         or
         <a class="drug drug_general" data-topicid="114899" href="/z/d/drug information/114899.html" rel="external">
          secnidazole
         </a>
         in pregnancy and thus we do not advise use of these drugs during pregnancy [
         <a href="#rid1">
          1,21,23,37,38
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H2154861178">
         <span class="h2">
          Males
         </span>
         <span class="headingEndMark">
          —
         </span>
         While other treatment options exist, preferred treatment for male patients with confirmed trichomoniasis include:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Preferred
         </strong>
         –
         <a class="drug drug_general" data-topicid="9646" href="/z/d/drug information/9646.html" rel="external">
          Metronidazole
         </a>
         2 g orally in a single dose [
         <a href="#rid1">
          1,17,32
         </a>
         ]. If the oral suspension is preferred to tablets or capsules, the dosing is: metronidazole oral suspension 2 g (20 mL), either as a single oral dose or in two divided oral doses of 1 g (10 mL) each, given on the same day [
         <a href="#rid33">
          33
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Alternatives
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <a class="drug drug_general" data-topicid="10205" href="/z/d/drug information/10205.html" rel="external">
          Tinidazole
         </a>
         2 g orally in a single dose [
         <a href="#rid1">
          1,19
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         OR
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <a class="drug drug_general" data-topicid="114899" href="/z/d/drug information/114899.html" rel="external">
          Secnidazole
         </a>
         2 g orally given as a single dose [
         <a href="#rid9">
          9,24,34
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         OR
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <a class="drug drug_general" data-topicid="9646" href="/z/d/drug information/9646.html" rel="external">
          Metronidazole
         </a>
         , 400 or 500 mg, orally twice daily for seven days [
         <a href="#rid17">
          17
         </a>
         ]. Dose selection is based on availability and type of oral formulation; the 500 mg dose of metronidazole is more commonly available. If the oral suspension is preferred, it is given as 250 mg (2.5 mL) orally three times daily for seven days [
         <a href="#rid33">
          33
         </a>
         ]. Although data supporting a longer course of therapy are lacking, this approach is described for individuals with recurrent or persistent infection [
         <a href="#rid17">
          17
         </a>
         ].
        </p>
        <p>
        </p>
        <p>
         The clinical evaluation and management of individuals with urethritis are discussed in detail separately. (See
         <a class="medical medical_review" href="/z/d/html/86698.html" rel="external">
          "Urethritis in adult males"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2784217190">
         <span class="h2">
          Sex partners
         </span>
         <span class="headingEndMark">
          —
         </span>
         All sex partners (female and/or male) of patients treated for trichomoniasis are treated concurrently with the goal of preventing reinfection of the index patient and/or spread to other sex contacts [
         <a href="#rid1">
          1
         </a>
         ].
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Treatment selection
         </strong>
         – Treatment selection is based on the individual's characteristics (eg, pregnant or not, genital anatomy, dosing preferences) and as presented above. (See
         <a class="local">
          'Treatment regimens'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Option for expedited partner treatment
         </strong>
         – Ideally, all sex partners undergo their own evaluation for trichomoniasis and other STIs but expedited partner therapy (EPT) is reasonable where permitted [
         <a href="#rid45">
          45,46
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Abstinence from sexual activity
         </strong>
         – After completion of therapy (single- or multi-dose), the patient and their sex partners should abstain from intercourse until
         <strong>
         </strong>
         all partners have completed antibiotic therapy
         <strong>
          and
         </strong>
         symptoms have resolved [
         <a href="#rid1">
          1
         </a>
         ]. There are no studies on how long trichomonads remain viable after treatment is initiated or completed. We counsel patients to abstain from anal intercourse as well because trichomonads have been found in rectal samples and an anal reservoir of organisms could be a source of reinfection [
         <a href="#rid47">
          47
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Concurrent carriage rates
         </strong>
         – Concurrent carriage rates of 30 to 70 percent have been reported in male sex partners [
         <a href="#rid48">
          48
         </a>
         ]. Concurrent carriage rates for female sex partners of female patients are not known.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1285622217">
         <span class="h2">
          Additional counseling
         </span>
         <span class="headingEndMark">
          —
         </span>
         Additional counseling for patients with confirmed trichomoniasis, or their sex partners, includes:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Sexual activity
         </strong>
         – Avoid genital sexual activity until all sex partners have completed antibiotic treatment
         <strong>
          and
         </strong>
         are asymptomatic [
         <a href="#rid1">
          1
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          STI testing
         </strong>
         – Testing for other STIs, including HIV, syphilis, gonorrhea, and chlamydia, and treatment as indicated, is advised for patients with confirmed infection
         <strong>
          and
         </strong>
         their sex partners [
         <a href="#rid1">
          1
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/7596.html" rel="external">
          "Screening for sexually transmitted infections"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2623643479">
         <span class="h1">
          REPEAT TESTING AFTER TREATMENT
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Female
         </strong>
         – We retest all female patients who were treated for a documented
         <em>
          Trichomonas
         </em>
         infection, regardless of whether they believe their sex partners were treated [
         <a href="#rid1">
          1
         </a>
         ]. The rationale is that rates of persistent infection or reinfection are high. Retrospective studies have reported positive retest rates of 24 to 44 percent for patients undergoing nucleic acid amplification tests (NAATs) within the guideline time frame [
         <a href="#rid49">
          49,50
         </a>
         ]. A single study in pregnant people, in which diagnosis could be made using NAAT or wet mount, found a similarly high prevalence of 29 percent upon retesting [
         <a href="#rid36">
          36
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/2896.html" rel="external">
          "Polymerase chain reaction (PCR)"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Repeat testing is ideally performed with a NAAT, which can be done no sooner than three weeks [
         <a href="#rid51">
          51
         </a>
         ] and up to three months after completing treatment, regardless of whether or not sex partner(s) were treated [
         <a href="#rid1">
          1
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         If testing is not possible within three months of initial treatment, then testing is advised up to 12 months from initial treatment [
         <a href="#rid1">
          1
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         If NAATs are not available, retesting with the same modality used to make the initial diagnosis (or a more sensitive test) is advised.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Male
         </strong>
         – Data to inform retesting previously treated male patients are lacking; there is no recommendation to retest these patients unless they are symptomatic [
         <a href="#rid1">
          1
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1877193140">
         <span class="h1">
          PATIENTS WITH PERSISTENT SYMPTOMS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Most cases of persistent symptoms result from inadequate initial treatment or reinfection by an untreated sex partner. Some patients will have persistent infection despite adequate initial treatment.
        </p>
        <p class="headingAnchor" id="H3817506860">
         <span class="h2">
          Diagnostic approach
         </span>
         <span class="headingEndMark">
          —
         </span>
         We take the following approach:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Patient history
         </strong>
         – Take a detailed history to determine if the persistent symptoms are likely from inadequate initial treatment or reinfection.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Diagnostic test
         </strong>
         – Retest patients with persistent symptoms with nucleic acid amplification testing (NAAT) to confirm trichomonas as the cause of the persistent symptoms as patients can have more than one infection. NAAT should not be repeated sooner than three weeks from completion of prior treatment because of potential for false-positive results [
         <a href="#rid1">
          1,51
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/5453.html" rel="external">
          "Trichomoniasis: Clinical manifestations and diagnosis", section on 'Preferred tests'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Exclude other causes
         </strong>
         – Other potential sources of symptoms, such as vulvovaginal candidiasis, bacterial vaginosis (BV), and the sexually transmitted infections gonorrhea and chlamydia, are excluded with appropriate tests. (See
         <a class="medical medical_review" href="/z/d/html/5477.html" rel="external">
          "Vaginitis in adults: Initial evaluation", section on 'Test vaginal discharge'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2243903379">
         <span class="h2">
          Treatment
         </span>
         <span class="headingEndMark">
          —
         </span>
         Treatment is based on diagnostic test results. As coinfection is common, all diagnosed potential causes of the patient's symptoms (eg, candidiasis, BV, trichomonas) are treated as indicated.
        </p>
        <p>
         For patients with confirmed persistent or recurrent trichomoniasis, we proceed through the treatment approaches as listed:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Inadequate initial treatment
         </strong>
         – The most common cause of continued symptoms and infection is medication misuse or early discontinuation that results in a persistent vaginal reservoir of organisms. For patients with recurrent symptoms and likely inadequate initial treatment, we discuss obstacles to completing therapy, explore possible solutions, and retreat with the initial regimens as above. Use of single-dose drugs may enhance medication completion in drug intolerant patients. (See
         <a class="local">
          'Treatment regimens'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Reinfection by sex partner
         </strong>
         – Reinfection from untreated or undertreated sexual partners is common. For patients with recurrent trichomoniasis in whom reinfection by a sex partner is likely, we repeat treatment of the patient, and all sex partners, with the originally selected treatment regimen as presented above. (See
         <a class="local">
          'Treatment regimens'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Persistent infection
         </strong>
         – Persistent infection can occur despite appropriate treatment of the patient and all sex partners. Once inadequate initial treatment and/or reinfection from a sex partner have been excluded, we retreat the index patient
         <strong>
          and
         </strong>
         all sex partners as follows:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Longer duration of treatment
         </strong>
         – Individuals with symptom recurrence after single-dose oral
         <a class="drug drug_general" data-topicid="9646" href="/z/d/drug information/9646.html" rel="external">
          metronidazole
         </a>
         2 g should be treated with oral metronidazole 500 mg twice daily for seven days (total dose 7 g) [
         <a href="#rid1">
          1,31
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Increased dose and duration of treatment
         </strong>
         – If the patient has persistent trichomonas infection despite multi-dose treatment, we then treat with higher doses of oral
         <a class="drug drug_general" data-topicid="10205" href="/z/d/drug information/10205.html" rel="external">
          tinidazole
         </a>
         or
         <a class="drug drug_general" data-topicid="9646" href="/z/d/drug information/9646.html" rel="external">
          metronidazole
         </a>
         .
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         <strong>
          Females
         </strong>
         –
         <a class="drug drug_general" data-topicid="9646" href="/z/d/drug information/9646.html" rel="external">
          Metronidazole
         </a>
         or
         <a class="drug drug_general" data-topicid="10205" href="/z/d/drug information/10205.html" rel="external">
          tinidazole
         </a>
         2 g orally once a day for seven days (total dose 14 g) can be used [
         <a href="#rid1">
          1,31
         </a>
         ]. This approach can also be effective in patients with low levels of metronidazole resistance, which was noted in 4 percent of 538
         <em>
          T. vaginalis
         </em>
         isolates collected from women attending STD clinics in six cities in the United States [
         <a href="#rid52">
          52
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         <strong>
          Males
         </strong>
         –
         <a class="drug drug_general" data-topicid="9646" href="/z/d/drug information/9646.html" rel="external">
          Metronidazole
         </a>
         2 g orally once daily for seven days (total dose 14 g) is advised [
         <a href="#rid1">
          1
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3322298344">
         <span class="h2">
          Drug-resistant infection
         </span>
         <span class="headingEndMark">
          —
         </span>
         If the above treatment regimens fail and NAAT confirms persistent trichomonas infection, next steps include in vitro culture and drug susceptibility testing and patient referral to a specialist [
         <a href="#rid4">
          4
         </a>
         ]. One option for culture and drug sensitivity testing is available through the United States CDC
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.cdc.gov%2Flaboratory%2Fspecimen-submission%2Fdetail.html%3FCDCTestCode%3DCDC-10239&amp;token=Fu9NdiIc39tUEyTDjnAAm0L7WEalHUkdqmRNz%2FDtJy6hCVwdxI9ramXmwQkfkisblAxFcQJHag1buTkMiU9GbhLczN%2Fd44mh8izXZdWjRaoBBHgg%2Bzh2M%2BrOtHIPcXdi&amp;TOPIC_ID=139046" target="_blank">
          Infectious Disease Laboratories
         </a>
         . Metronidazole-resistant
         <em>
          T. vaginalis
         </em>
         has been documented [
         <a href="#rid53">
          53-55
         </a>
         ]. Cross resistance to
         <a class="drug drug_general" data-topicid="10205" href="/z/d/drug information/10205.html" rel="external">
          tinidazole
         </a>
         is frequent but not inevitable [
         <a href="#rid53">
          53,56
         </a>
         ]. For
         <a class="drug drug_general" data-topicid="114899" href="/z/d/drug information/114899.html" rel="external">
          secnidazole
         </a>
         , trichomoniasis isolates requiring a minimum inhibitory concentration similar to that of
         <a class="drug drug_general" data-topicid="9646" href="/z/d/drug information/9646.html" rel="external">
          metronidazole
         </a>
         have been reported [
         <a href="#rid55">
          55
         </a>
         ]. In an in vitro study of trichomonas isolates in South Africa, resistance to metronidazole was more common (11 percent) than tinidazole (2 percent) or secnidazole (1 percent) [
         <a href="#rid3">
          3
         </a>
         ].
        </p>
        <p>
         Treatment options for patients with metronidazole-resistant infection include:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          High-dose
         </strong>
         <strong>
          tinidazole
         </strong>
         – Refractory disease has been successfully treated with high-dose oral
         <a class="drug drug_general" data-topicid="10205" href="/z/d/drug information/10205.html" rel="external">
          tinidazole
         </a>
         , although the optimal dose, regimen, and combination with other drugs have not been established [
         <a href="#rid4">
          4,57-59
         </a>
         ]. Choice of treatment is based on availability of the drugs below.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Tinidazole
         </strong>
         <strong>
          only
         </strong>
         – Oral
         <a class="drug drug_general" data-topicid="10205" href="/z/d/drug information/10205.html" rel="external">
          tinidazole
         </a>
         2 g daily for 14 days
         <strong>
          plus
         </strong>
         vaginal tinidazole 500 mg twice a day for 14 days (total drug dose 42 g) [
         <a href="#rid57">
          57
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Tinidazole
         </strong>
         <strong>
          plus
         </strong>
         <a class="drug drug_general" data-topicid="134822" href="/z/d/drug information/134822.html" rel="external">
          vaginal boric acid
         </a>
         –
         <a class="drug drug_general" data-topicid="10205" href="/z/d/drug information/10205.html" rel="external">
          Tinidazole
         </a>
         , 1 g orally three time a day for 14 days
         <strong>
          plus
         </strong>
         vaginal boric acid, 600 mg, twice daily for 28 days successfully treated a female patient with confirmed
         <em>
          T. vaginalis
         </em>
         infection resistant to both
         <a class="drug drug_general" data-topicid="9646" href="/z/d/drug information/9646.html" rel="external">
          metronidazole
         </a>
         and tinidazole [
         <a href="#rid60">
          60
         </a>
         ]. Boric acid should
         <strong>
          never
         </strong>
         be given orally as it can cause death.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Tinidazole
         </strong>
         <strong>
          plus vaginal
         </strong>
         <strong>
          paromomycin
         </strong>
         –
         <a class="drug drug_general" data-topicid="10205" href="/z/d/drug information/10205.html" rel="external">
          Tinidazole
         </a>
         1 g orally three times a day
         <strong>
          plus
         </strong>
         vaginal
         <a class="drug drug_general" data-topicid="9742" href="/z/d/drug information/9742.html" rel="external">
          paromomycin
         </a>
         6.25% given as 4 g intravaginally at night (ie, 250 mg of drug per dose), both for a total of 14 days, has been reported in one patient [
         <a href="#rid61">
          61
         </a>
         ]. Additional information on vaginal paromomycin is presented in the bullet below.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="114899" href="/z/d/drug information/114899.html" rel="external">
          Secnidazole
         </a>
         – Data supporting secnidazole treatment of drug-resistant trichomoniasis is limited to one case report. A patient with confirmed metronidazole- and tinidazole-resistant infection was successfully treated with an investigational protocol of secnidazole 2 g orally daily for 14 days combined with boric acid 600 mg suppository vaginally twice daily for 14 days [
         <a href="#rid62">
          62
         </a>
         ]. Four weeks after completing treatment, the patient’s symptoms had resolved and test of cure was negative by wet mount, culture, and NAAT.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Vaginal
         </strong>
         <strong>
          paromomycin
         </strong>
         – Rare patients who do not have a response to 5-nitroimidazoles have been treated with the aminoglycoside
         <a class="drug drug_general" data-topicid="9742" href="/z/d/drug information/9742.html" rel="external">
          paromomycin
         </a>
         . Paromomycin 6.25% cream is given as a 4 g intravaginal dose (ie, 250 mg of drug) daily for two weeks) [
         <a href="#rid63">
          63
         </a>
         ]. Dual therapy combining intravaginal paromomycin 6.25% cream, 4 g intravaginally at night, with oral
         <a class="drug drug_general" data-topicid="10205" href="/z/d/drug information/10205.html" rel="external">
          tinidazole
         </a>
         , 1 g three times daily, for a total of 14 days, has been reported [
         <a href="#rid61">
          61
         </a>
         ]. Intravaginal paromomycin can cause local side effects (pain, mucosal ulceration) but these symptoms are self-limited [
         <a href="#rid64">
          64,65
         </a>
         ]. Applying lubricating jelly to the vaginal tissue prior to vaginal paromomycin application has been reported to reduce ulceration in some patients [
         <a href="#rid65">
          65
         </a>
         ]. Paromomycin is not available commercially in the United States as a cream and must be compounded by a specialty pharmacy. For this reason, we consider it a third-line option when the above regimens have not worked.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="134822" href="/z/d/drug information/134822.html" rel="external">
          Vaginal boric acid
         </a>
         – Successful treatment of drug-resistant trichomoniasis has been reported with vaginal boric acid, alone [
         <a href="#rid66">
          66
         </a>
         ] or combination with other drugs (eg,
         <a class="drug drug_general" data-topicid="114899" href="/z/d/drug information/114899.html" rel="external">
          secnidazole
         </a>
         [
         <a href="#rid62">
          62
         </a>
         ] or
         <a class="drug drug_general" data-topicid="9287" href="/z/d/drug information/9287.html" rel="external">
          clotrimazole
         </a>
         [
         <a href="#rid67">
          67
         </a>
         ]).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Limited data
         </strong>
         – Case reports have described successful use of nimorazole, ornidazole, niridazole, furazolidone, and hamycin [
         <a href="#rid68">
          68
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Not advised
         </strong>
         – Other topical agents that have a limited (&lt;50 percent) cure rate and therefore are not recommended include vaginal
         <strong>
         </strong>
         povidone-iodine,
         <a class="drug drug_general" data-topicid="9287" href="/z/d/drug information/9287.html" rel="external">
          clotrimazole
         </a>
         ,
         <a class="drug drug_general" data-topicid="9277" href="/z/d/drug information/9277.html" rel="external">
          acetic acid
         </a>
         , furazolidone,
         <a class="drug drug_general" data-topicid="8749" href="/z/d/drug information/8749.html" rel="external">
          gentian violet
         </a>
         ,
         <a class="drug drug_general" data-topicid="10170" href="/z/d/drug information/10170.html" rel="external">
          nonoxynol-9
         </a>
         , and potassium permanganate [
         <a href="#rid69">
          69
         </a>
         ]. A trial of
         <a class="drug drug_general" data-topicid="10105" href="/z/d/drug information/10105.html" rel="external">
          nitazoxanide
         </a>
         in three women with difficult to eradicate
         <em>
          T. vaginalis
         </em>
         reported lack of efficacy [
         <a href="#rid70">
          70
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H140938901">
         <span class="h1">
          UNIQUE POPULATIONS
         </span>
        </p>
        <p class="headingAnchor" id="H624271883">
         <span class="h2">
          Allergy to 5-nitroimidazole drugs
         </span>
         <span class="headingEndMark">
          —
         </span>
         Given the low efficacy of alternate drug therapies, we suggest patients with an IgE-mediated allergy to
         <a class="drug drug_general" data-topicid="9646" href="/z/d/drug information/9646.html" rel="external">
          metronidazole
         </a>
         or
         <a class="drug drug_general" data-topicid="10205" href="/z/d/drug information/10205.html" rel="external">
          tinidazole
         </a>
         be referred for desensitization rather than using an alternative class of drugs [
         <a href="#rid1">
          1,65
         </a>
         ]. In one series, all 15 people who underwent desensitization subsequently eradicated their infection [
         <a href="#rid71">
          71
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/2079.html" rel="external">
          "An approach to the patient with drug allergy"
         </a>
         .)
        </p>
        <p>
         Data supporting treatment options for patients who cannot undergo or do not respond to desensitization therapy are limited. In a case report of one patient who was unable to complete
         <a class="drug drug_general" data-topicid="9646" href="/z/d/drug information/9646.html" rel="external">
          metronidazole
         </a>
         desensitization therapy, the individual with successfully treated with
         <a class="drug drug_general" data-topicid="10205" href="/z/d/drug information/10205.html" rel="external">
          tinidazole
         </a>
         [
         <a href="#rid72">
          72
         </a>
         ]. A single case report describes successful treatment with
         <a class="drug drug_general" data-topicid="114899" href="/z/d/drug information/114899.html" rel="external">
          secnidazole
         </a>
         in a person with reported metronidazole hypersensitivity [
         <a href="#rid73">
          73
         </a>
         ]. Therapy with drugs other than 5-nitroimidazoles is an option, but cure rates have been low (≤50 percent) [
         <a href="#rid10">
          10,74
         </a>
         ]. Case reports have noted microbiologic and symptomatic cure following long-term treatment with
         <a class="drug drug_general" data-topicid="134822" href="/z/d/drug information/134822.html" rel="external">
          vaginal boric acid
         </a>
         , 600 mg intravaginally twice daily, alone or in combination with other agents, for at least 60 days [
         <a href="#rid65">
          65
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H3780273760">
         <span class="h2">
          Lactation
         </span>
         <span class="headingEndMark">
          —
         </span>
         <a class="drug drug_general" data-topicid="9646" href="/z/d/drug information/9646.html" rel="external">
          Metronidazole
         </a>
         is the preferred drug for use in lactating patients.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Metronidazole
         </strong>
         <strong>
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Our approach
         </strong>
         – We treat breastfeeding individuals with
         <a class="drug drug_general" data-topicid="9646" href="/z/d/drug information/9646.html" rel="external">
          metronidazole
         </a>
         500 mg orally twice a day for seven days. The drug dose received through breast milk is lower than what would be used for to treat infection in infants [
         <a href="#rid1">
          1,75
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Alternate dose
         </strong>
         –
         <a class="drug drug_general" data-topicid="9646" href="/z/d/drug information/9646.html" rel="external">
          Metronidazole
         </a>
         400 mg orally three times a day for seven days.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         While one study reported that three times daily dosing produced a lower
         <a class="drug drug_general" data-topicid="9646" href="/z/d/drug information/9646.html" rel="external">
          metronidazole
         </a>
         concentration in breast milk [
         <a href="#rid76">
          76
         </a>
         ], limitations include that the study included only seven infants, more frequent dosing may be more challenging for patients, and 400 mg tablets are not universally available.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Option to defer breastfeeding (ie, pump and dump)
         </strong>
         – Although adverse effects have not been reported from infant exposure to maternal oral
         <a class="drug drug_general" data-topicid="9646" href="/z/d/drug information/9646.html" rel="external">
          metronidazole
         </a>
         , some clinicians advise deferring breastfeeding for 12 to 24 hours following maternal single-dose treatment because the relative infant dose of metronidazole is high (29 percent) with maternal administration of the 2 g one-time dose [
         <a href="#rid77">
          77
         </a>
         ]. For patients who wish to avoid any metronidazole exposure to their infants, we advise pumping and expelling breast milk for 12 hours. Comparative data for the 12- and 24-hour time windows are lacking; deferring breastfeeding for 24 hours may be challenging.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Tinidazole
         </strong>
         – Lactating patients who require treatment with oral
         <a class="drug drug_general" data-topicid="10205" href="/z/d/drug information/10205.html" rel="external">
          tinidazole
         </a>
         , which has a longer half-life than
         <a class="drug drug_general" data-topicid="9646" href="/z/d/drug information/9646.html" rel="external">
          metronidazole
         </a>
         , are advised to defer breastfeeding (ie, pump and dump) for 72 hours (three days) after a single 2 g dose [
         <a href="#rid1">
          1
         </a>
         ]. Although data from human studies are limited, animal studies suggest tinidazole may be associated with risk to the infant. (See
         <a class="local">
          'Teratogenicity'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="114899" href="/z/d/drug information/114899.html" rel="external">
          Secnidazole
         </a>
         – Data on safety of secnidazole use during lactation are lacking. Given the long half-life of the drug (approximately 17 hours), the manufacturer advises avoiding giving milk to the infant for 96 hours after a single dose [
         <a href="#rid78">
          78,79
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2880661469">
         <span class="h2">
          HIV infection
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Treatment and retesting
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Female
         </strong>
         – Female patients with HIV infection and
         <em>
          T. vaginalis
         </em>
         are treated with
         <a class="drug drug_general" data-topicid="9646" href="/z/d/drug information/9646.html" rel="external">
          metronidazole
         </a>
         500 mg twice per day for seven days [
         <a href="#rid1">
          1,80
         </a>
         ]. We do not use single-dose metronidazole in this population given the high prevalence of asymptomatic bacterial vaginosis (BV) coinfection and other factors that may render single-dose oral metronidazole less effective. Female patients are retested for trichomoniasis three months after completion of therapy, preferably with NAAT. (See
         <a class="medical medical_review" href="/z/d/html/5453.html" rel="external">
          "Trichomoniasis: Clinical manifestations and diagnosis", section on 'Preferred tests'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Male
         </strong>
         – Male patients receive the same treatment and retesting approaches regardless of HIV infection status. Treatment with
         <a class="drug drug_general" data-topicid="9646" href="/z/d/drug information/9646.html" rel="external">
          metronidazole
         </a>
         2 g in a single oral dose is advised; retesting of male patients is not recommended at this time [
         <a href="#rid1">
          1
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Sex partners
         </strong>
         – As with other populations, sex partners of HIV-infected patients with
         <em>
          T. vaginalis
         </em>
         infection should be treated as well. (See
         <a class="local">
          'Sex partners'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Supporting data for multi-dose
         </strong>
         <a class="drug drug_general" data-topicid="9646" href="/z/d/drug information/9646.html" rel="external">
          metronidazole
         </a>
         <strong>
          for female patients
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         In a trial where 270 HIV-positive women with culture-confirmed
         <em>
          T. vaginalis
         </em>
         were randomly assigned to treatment with
         <a class="drug drug_general" data-topicid="9646" href="/z/d/drug information/9646.html" rel="external">
          metronidazole
         </a>
         2 g single dose or metronidazole 500 mg twice per day for seven days, single-dose therapy was less effective than multi-dose therapy [
         <a href="#rid80">
          80
         </a>
         ]. The seven-day treatment group had a lower rate of positive cultures 6 to 12 days after treatment completion (8.5 percent [11 in 130 women] versus 16.8 percent [21 in 125 women]; relative risk [RR] 0.5, 95% CI 0.25-1.00) and at three months (11 percent [8 in 73 women] versus 24.1 percent [19 in 79 women]; RR 0.46, 95% CI 0.21-0.98). Of note, all women were given a 2 g oral metronidazole dose to deliver to their sex partners.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         In another trial, HIV-infected women on antiretroviral therapy had 2.6-fold greater risk of persistent trichomoniasis than HIV-infected women not on antiretroviral therapy, but this risk could be minimized by multiday dosing [
         <a href="#rid81">
          81
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Bacterial vaginosis coinfection
         </strong>
         – There is a high prevalence of BV in patients with concurrent HIV and
         <em>
          T. vaginalis
         </em>
         infection and an apparent association between the presence of BV and early failure of single-dose oral
         <a class="drug drug_general" data-topicid="9646" href="/z/d/drug information/9646.html" rel="external">
          metronidazole
         </a>
         treatment of trichomoniasis [
         <a href="#rid82">
          82
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/3753.html" rel="external">
          "HIV and women", section on 'Bacterial vaginosis, genital ulcers, and pelvic inflammatory disease'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/113103.html" rel="external">
          "Bacterial vaginosis: Initial treatment"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1055746758">
         <span class="h2">
          Immunosuppression
         </span>
         <span class="headingEndMark">
          —
         </span>
         We treat immunosuppressed patients with
         <a class="drug drug_general" data-topicid="9646" href="/z/d/drug information/9646.html" rel="external">
          metronidazole
         </a>
         500 mg orally daily for seven days. As limited data are available to address the wide spectrum of immunosuppression, treatment of these patients is extrapolated from data based on patients with HIV infection.
        </p>
        <p class="headingAnchor" id="H1520973110">
         <span class="h2">
          Transgender individuals
         </span>
         <span class="headingEndMark">
          —
         </span>
         There are no available data indicating that hormone therapy or surgery should alter trichomoniasis treatment or retesting recommendations. We extrapolate from the above data to transgender patients and treat or retest based on the patient's anatomy.
        </p>
        <p class="headingAnchor" id="H4119077963">
         <span class="h1">
          SOCIETY GUIDELINE LINKS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See
         <a class="medical medical_society_guidelines" href="/z/d/html/111582.html" rel="external">
          "Society guideline links: Sexually transmitted infections"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1135603052">
         <span class="h1">
          INFORMATION FOR PATIENTS
         </span>
         <span class="headingEndMark">
          —
         </span>
         UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5
         <sup>
          th
         </sup>
         to 6
         <sup>
          th
         </sup>
         grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10
         <sup>
          th
         </sup>
         to 12
         <sup>
          th
         </sup>
         grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.
        </p>
        <p>
         Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Basics topic (see
         <a class="medical medical_basics" href="/z/d/html/16999.html" rel="external">
          "Patient education: Trichomoniasis (The Basics)"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2729560071">
         <span class="h1">
          RESOURCES FOR PATIENTS AND CLINICIANS
         </span>
         <span class="headingEndMark">
          —
         </span>
         The following resources are available to patients and clinicians at no cost.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         World Health Organization (WHO) –
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.who.int%2Fpublications%2Fi%2Fitem%2F9789240024168&amp;token=mr3MkQMxxRm373pPGLTYB%2B8L7rJeOJtqYOfpSLq18h7bLDDnWC3XicBcpsIGU3t1LZa9hAfcC%2BHlHSr8RBLKzQ%3D%3D&amp;TOPIC_ID=139046" target="_blank">
          Guidelines for the management of symptomatic sexually transmitted infections
         </a>
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         National Health Service (UK) –
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.nhs.uk%2Fconditions%2Ftrichomoniasis%2F&amp;token=lblfowwGB6QwC91WNuiIf8xpMoOf93JvR%2B5FfnZb735o2QcnvUhNF9CurY%2FgCefa52Q0euYEQoD%2Fimi0oqCrZA%3D%3D&amp;TOPIC_ID=139046" target="_blank">
          Trichomoniasis
         </a>
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         US Centers for Disease Control and Prevention (CDC) –
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.cdc.gov%2Fstd%2Ftreatment-guidelines%2Fdefault.htm&amp;token=GG%2FgjfxydbWPRfxXxvkuO3Z7rCvPfYCbHpI0XhRbEzgb1PiLFQLuos1hzlgAVwGZBa1nyF6yQEYtZyuOXda5Pg%3D%3D&amp;TOPIC_ID=139046" target="_blank">
          STI Treatment Guidelines
         </a>
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         American College of Obstetricians and Gynecologists –
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.acog.org%2Fclinical%2Fclinical-guidance%2Fpractice-bulletin%2Farticles%2F2020%2F01%2Fvaginitis-in-nonpregnant-patients&amp;token=KA%2FhYG%2B2X0fUeDLhyM3yJEG%2Bu3V5Midqf%2BDOXNyMYJE3iCbsp7OEbDkED7fsARoJmxxETaM%2B1TWlbQqLPCtzSQFR6hKQholIe25Q%2FpE9xRjRKBnkI9Oevk4QAsHayqC32PoX%2BzN5lSaK67y4atLMGg%3D%3D&amp;TOPIC_ID=139046" target="_blank">
          Vaginitis in Nonpregnant Patients
         </a>
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H514350466">
         <span class="h1">
          SUMMARY AND RECOMMENDATIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Whom to treat
         </strong>
         – As with any sexually transmitted infection (STI), treatment is indicated for all persons with confirmed
         <em>
          T. vaginalis
         </em>
         infection, symptomatic and asymptomatic, as well as their sexual partners (even if asymptomatic). Treatment has limited side effects, is associated with a high cure rate, likely reduces the prevalence of
         <em>
          T. vaginalis
         </em>
         carriage in the population, reduces transmission, and reduces the risk of sequelae (including acquisition/transmission of HIV and adverse pregnancy outcomes). (See
         <a class="local">
          'Whom to treat'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Therapeutic drugs and selection
         </strong>
         – The 5-nitroimidazole drugs (
         <a class="drug drug_general" data-topicid="9646" href="/z/d/drug information/9646.html" rel="external">
          metronidazole
         </a>
         ,
         <a class="drug drug_general" data-topicid="10205" href="/z/d/drug information/10205.html" rel="external">
          tinidazole
         </a>
         , and
         <a class="drug drug_general" data-topicid="114899" href="/z/d/drug information/114899.html" rel="external">
          secnidazole
         </a>
         ) are the only class of drugs that cure trichomonas infection  (
         <a class="graphic graphic_algorithm graphicRef132757" href="/z/d/graphic/132757.html" rel="external">
          algorithm 1
         </a>
         ). Selection is based on patient characteristics (eg, genital anatomy, pregnancy), patient preferences regarding dosing, and drug availability. (See
         <a class="local">
          'Drugs and descriptions'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Female patients
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Preferred
         </strong>
         – For female patients, including those who are pregnant (regardless of trimester), we suggest multi-dose therapy with oral
         <a class="drug drug_general" data-topicid="9646" href="/z/d/drug information/9646.html" rel="external">
          metronidazole
         </a>
         (preferred, capsule or tablet 500 mg orally twice daily for seven days, or oral suspension 250 mg (2.5 mL) orally three times daily for seven days)  (
         <a class="graphic graphic_algorithm graphicRef132757" href="/z/d/graphic/132757.html" rel="external">
          algorithm 1
         </a>
         ) (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ). Treatment with metronidazole vaginal gel is not effective and should not be used to treat trichomoniasis. (See
         <a class="local">
          'Females'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Alternatives
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         <strong>
          Nonpregnant
         </strong>
         – For nonpregnant females, alternative treatments include single-dose
         <a class="drug drug_general" data-topicid="10205" href="/z/d/drug information/10205.html" rel="external">
          tinidazole
         </a>
         or
         <a class="drug drug_general" data-topicid="114899" href="/z/d/drug information/114899.html" rel="external">
          secnidazole
         </a>
         (2 g orally once for either drug) or
         <a class="drug drug_general" data-topicid="9646" href="/z/d/drug information/9646.html" rel="external">
          metronidazole
         </a>
         oral suspension [2 g (20 mL) as a single dose or in two divided doses of 1 g (10 mL) each, given on the same day]. Single-dose treatment may appeal to those who are unable to complete a seven-day treatment regimen or who prefer single-day dosing. (See
         <a class="local">
          'Nonpregnant'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         <strong>
          Pregnant
         </strong>
         – Single-day
         <a class="drug drug_general" data-topicid="9646" href="/z/d/drug information/9646.html" rel="external">
          metronidazole
         </a>
         is a reasonable treatment option for pregnant persons who are unable to complete a seven-day course of treatment. However, we do not use
         <a class="drug drug_general" data-topicid="10205" href="/z/d/drug information/10205.html" rel="external">
          tinidazole
         </a>
         or
         <a class="drug drug_general" data-topicid="114899" href="/z/d/drug information/114899.html" rel="external">
          secnidazole
         </a>
         during pregnancy, especially in the first trimester, as data from human pregnancies are limited and studies in animals suggest risk. (See
         <a class="local">
          'Pregnant'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Male patients
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Initial episode
         </strong>
         – For male individuals, we suggest single-dose treatment with
         <a class="drug drug_general" data-topicid="9646" href="/z/d/drug information/9646.html" rel="external">
          metronidazole
         </a>
         ,
         <a class="drug drug_general" data-topicid="10205" href="/z/d/drug information/10205.html" rel="external">
          tinidazole
         </a>
         , or
         <a class="drug drug_general" data-topicid="114899" href="/z/d/drug information/114899.html" rel="external">
          secnidazole
         </a>
         (2 g orally given once) (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ). Single-day therapy with an oral 5-nitroimidazole is easier to use compared with multi-dose regimens. Although treatment efficacy may be lower with single-dose metronidazole compared with multi-dose regimens, the available data are inadequate to make a definitive conclusion. Choice of drug is based on availability and cost. For patients unable to tolerate capsules or tablets, metronidazole oral suspension is available. (See
         <a class="local">
          'Males'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Recurrent infection
         </strong>
         – Patients who have recurrent or persistent infection despite single-dose treatment may reasonably be treated with a seven-day course of oral
         <a class="drug drug_general" data-topicid="9646" href="/z/d/drug information/9646.html" rel="external">
          metronidazole
         </a>
         (capsule or tablet 500 mg orally twice daily for seven days, or oral suspension 250 mg [2.5 mL] orally three times daily for seven days), although supporting data are lacking.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Sex partners
         </strong>
         – For
         <strong>
          all
         </strong>
         sex partners of patients with confirmed trichomoniasis, we suggest concurrent treatment for trichomoniasis rather than observation (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ). Treatment selection is based on the individual's anatomy. Ideally, all sex partners should undergo their own evaluation for trichomoniasis and other STIs but expedited partner therapy (EPT) is reasonable where permitted. (See
         <a class="local">
          'Sex partners'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          HIV infection
         </strong>
         – Patients with HIV infection receive the same treatment approach as listed above. For patients with a vagina, preferred treatment is
         <a class="drug drug_general" data-topicid="9646" href="/z/d/drug information/9646.html" rel="external">
          metronidazole
         </a>
         500 mg orally twice daily for seven days because shorter treatment duration is associated with lower treatment efficacy. (See
         <a class="local">
          'HIV infection'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Transgender patients
         </strong>
         – In the absence of data to inform practice, we extrapolate the above treatment approaches to transgender patients based on their genital anatomy. (See
         <a class="local">
          'Transgender individuals'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Additional counseling points
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Sexual activity
         </strong>
         – Patients with confirmed trichomonas and their sex partners should avoid genital and anal sexual activity until all sex partners have completed treatment
         <strong>
          and
         </strong>
         are asymptomatic. (See
         <a class="local">
          'Additional counseling'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          STI testing
         </strong>
         – Patients with confirmed trichomonas and their sex partners are offered testing for HIV and other STIs. For those who cannot access evaluation and treatment, EPT is a reasonable option where permitted. (See
         <a class="local">
          'Additional counseling'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Repeat testing
         </strong>
         – Female patients treated for a documented trichomonas infection should be retested with nucleic acid amplification tests (NAATs) between three weeks and three months of completing treatment. As data to inform an approach for male patients are inadequate, there is no recommendation to retest these patients unless they are symptomatic. In absence of data to inform practice, we extrapolate these approaches to transgender patients. (See
         <a class="local">
          'Repeat testing after treatment'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Refractory infection
         </strong>
         – Treatment with an increased dose and/or duration of
         <a class="drug drug_general" data-topicid="9646" href="/z/d/drug information/9646.html" rel="external">
          metronidazole
         </a>
         or
         <a class="drug drug_general" data-topicid="10205" href="/z/d/drug information/10205.html" rel="external">
          tinidazole
         </a>
         are the primary options for patients with refractory trichomoniasis. (See
         <a class="local">
          'Patients with persistent symptoms'
         </a>
         above.)
        </p>
        <p>
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Workowski KA, Bachmann LH, Chan PA, et al. Sexually Transmitted Infections Treatment Guidelines, 2021. MMWR Recomm Rep 2021; 70:1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Heine P, McGregor JA. Trichomonas vaginalis: A reemerging pathogen. Clin Obstet Gynecol 1993; 36:137.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mtshali A, Ngcapu S, Govender K, et al. In Vitro Effect of 5-Nitroimidazole Drugs against Trichomonas vaginalis Clinical Isolates. Microbiol Spectr 2022; 10:e0091222.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Van Gerwen OT, Opsteen SA, Graves KJ, Muzny CA. Trichomoniasis. Infect Dis Clin North Am 2023; 37:245.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schwebke JR, Burgess D. Trichomoniasis. Clin Microbiol Rev 2004; 17:794.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hager WD, Brown ST, Kraus SJ, et al. Metronidazole for vaginal trichomoniasis. Seven-day vs single-dose regimens. JAMA 1980; 244:1219.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Manorama HT, Shenoy DR. Single-dose oral treatment of vaginal trichomoniasis with tinidazole and metronidazole. J Int Med Res 1978; 6:46.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Forna F, Gülmezoglu AM. Interventions for treating trichomoniasis in women. Cochrane Database Syst Rev 2003; :CD000218.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Muzny CA, Schwebke JR, Nyirjesy P, et al. Efficacy and Safety of Single Oral Dosing of Secnidazole for Trichomoniasis in Women: Results of a Phase 3, Randomized, Double-Blind, Placebo-Controlled, Delayed-Treatment Study. Clin Infect Dis 2021; 73:e1282.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tidwell BH, Lushbaugh WB, Laughlin MD, et al. A double-blind placebo-controlled trial of single-dose intravaginal versus single-dose oral metronidazole in the treatment of trichomonal vaginitis. J Infect Dis 1994; 170:242.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           duBouchet L, McGregor JA, Ismail M, McCormack WM. A pilot study of metronidazole vaginal gel versus oral metronidazole for the treatment of Trichomonas vaginalis vaginitis. Sex Transm Dis 1998; 25:176.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kissinger P, Muzny CA, Mena LA, et al. Single-dose versus 7-day-dose metronidazole for the treatment of trichomoniasis in women: an open-label, randomised controlled trial. Lancet Infect Dis 2018; 18:1251.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Howe K, Kissinger PJ. Single-dose compared with multidose metronidazole for the treatment of Trichomoniasis in women: A meta-analysis. Sex Transm Dis 2017; 44:29.
          </a>
         </li>
         <li class="breakAll">
          FLAGYL- metronidazole capsule. US Food and Drug Administration (FDA) approved product information. Revised December, 2021. US National Library of Medicine. www.dailymed.nlm.nih.gov (Accessed on June 30, 2022).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Van Gerwen OT, Camino AF, Sharma J, et al. Epidemiology, Natural History, Diagnosis, and Treatment of Trichomonas vaginalis in Men. Clin Infect Dis 2021; 73:1119.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Latif AS, Mason PR, Marowa E. Urethral trichomoniasis in men. Sex Transm Dis 1987; 14:9.
          </a>
         </li>
         <li class="breakAll">
          Guidelines for the management of symptomatic sexually transmitted infections. World Health Organization. July, 2021. https://www.who.int/publications/i/item/9789240024168. (Accessed on June 30, 2022).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Vaginitis in Nonpregnant Patients: ACOG Practice Bulletin, Number 215. Obstet Gynecol 2020; 135:e1. Reaffirmed 2022.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kawamura N. Metronidazole and tinidazole in a single large dose for treating urogenital infections with Trichomonas vaginalis in men. Br J Vener Dis 1978; 54:81.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pentikis HS, Adetoro N. Two Phase 1, Open-Label, Single-Dose, Randomized, Crossover Studies to Assess the Pharmacokinetics, Safety, and Tolerability of Orally Administered Granules of Secnidazole (2 g) in Healthy Female Volunteers Under Different Administration Conditions. Clin Pharmacol Drug Dev 2018; 7:543.
          </a>
         </li>
         <li class="breakAll">
          SOLOSEC- secnidazole granule. US Food and Drug Administration (FDA) approved product information. Revised June 2021. US National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=551e43d5-f700-4d6e-8029-026f8a8932ff (Accessed on July 22, 2021).
         </li>
         <li class="breakAll">
          Solosec- secnidazole granule. US Food and Drug Administration (FDA) approved product information. Revised July, 2022. US National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed/index.cfm (Accessed on September 20, 2022).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Muzny CA, Van Gerwen OT, Legendre D. Secnidazole: a treatment for trichomoniasis in adolescents and adults. Expert Rev Anti Infect Ther 2022; 20:1067.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ozbilgin A, Ozbel Y, Alkan MZ, et al. Trichomoniasis in non-gonococcic urethritis among male patients. J Egypt Soc Parasitol 1994; 24:621.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Williams CS, Woodcock KR. Do ethanol and metronidazole interact to produce a disulfiram-like reaction? Ann Pharmacother 2000; 34:255.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fjeld H, Raknes G. [Is combining metronidazole and alcohol really hazardous?]. Tidsskr Nor Laegeforen 2014; 134:1661.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mergenhagen KA, Wattengel BA, Skelly MK, et al. Fact versus Fiction: a Review of the Evidence behind Alcohol and Antibiotic Interactions. Antimicrob Agents Chemother 2020; 64.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kalaria SN, Gopalakrishnan M, Heil EL. A Population Pharmacokinetics and Pharmacodynamic Approach To Optimize Tazobactam Activity in Critically Ill Patients. Antimicrob Agents Chemother 2020; 64.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gupta NK, Woodley CL, Fried R. Effect of metronidazole on liver alcohol dehydrogenase. Biochem Pharmacol 1970; 19:2805.
          </a>
         </li>
         <li class="breakAll">
          Trichomoniasis. National Health Service. United Kingdom. November, 2021. https://www.nhs.uk/conditions/trichomoniasis/#:~:text=Treating%20trichomoniasis&amp;text=Most%20men%20and%20women%20are,clears%20up%20to%20prevent%20reinfection. (Accessed on June 30, 2022).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sherrard J, Pitt R, Hobbs KR, et al. British Association for Sexual Health and HIV (BASHH) United Kingdom national guideline on the management of Trichomonas vaginalis 2021. Int J STD AIDS 2022; 33:740.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tuddenham S, Hamill MM, Ghanem KG. Diagnosis and Treatment of Sexually Transmitted Infections: A Review. JAMA 2022; 327:161.
          </a>
         </li>
         <li class="breakAll">
          LIKMEZ- metronidazole oral suspension. US Food and Drug Administration (FDA) approved product information. Revised September 20, 2023. US National Library of Medicine. www.dailymed.nlm.nih.gov/dailymed/index.cfm (Accessed on October 23, 2023).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Muzny CA, Van Gerwen OT. Secnidazole for Trichomoniasis in Women and Men. Sex Med Rev 2022; 10:255.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Silver BJ, Guy RJ, Kaldor JM, et al. Trichomonas vaginalis as a cause of perinatal morbidity: A systematic review and meta-analysis. Sex Transm Dis 2014; 41:369.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kim TG, Young MR, Goggins ER, et al. Trichomonas vaginalis in Pregnancy: Patterns and Predictors of Testing, Infection, and Treatment. Obstet Gynecol 2020; 135:1136.
          </a>
         </li>
         <li class="breakAll">
          TINIDAZOLE- tinidazole tablet. US Food and Drug Administration (FDA) approved product information. Revised Dec 2019. US National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed/index.cfm (Accessed on July 06, 2021).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pentikis H, Eder S, Kaufman G, Chavousti S. Secnidazole, an approved single dose drug for bacterial vaginosis, does not cause reproductive toxicity in animals. Obstet Gynecol 2020; 135:25.
          </a>
         </li>
         <li class="breakAll">
          Drugs in Pregnancy and Lactation, 10, Briggs GG, Freeman RK (Eds), Wolters Kluwer Health, Philadelphia 2015. p.905.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mann JR, McDermott S, Zhou L, et al. Treatment of trichomoniasis in pregnancy and preterm birth: An observational study. J Womens Health (Larchmt) 2009; 18:493.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Stringer E, Read JS, Hoffman I, et al. Treatment of trichomoniasis in pregnancy in sub-Saharan Africa does not appear to be associated with low birth weight or preterm birth. S Afr Med J 2010; 100:58.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Goldenberg RL, Mwatha A, Read JS, et al. The HPTN 024 Study: The efficacy of antibiotics to prevent chorioamnionitis and preterm birth. Am J Obstet Gynecol 2006; 194:650.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ugwumadu A, Reid F, Hay P, Manyonda I. Natural history of bacterial vaginosis and intermediate flora in pregnancy and effect of oral clindamycin. Obstet Gynecol 2004; 104:114.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Caro-Patón T, Carvajal A, Martin de Diego I, et al. Is metronidazole teratogenic? A meta-analysis. Br J Clin Pharmacol 1997; 44:179.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kissinger P, Schmidt N, Mohammed H, et al. Patient-delivered partner treatment for Trichomonas vaginalis infection: A randomized controlled trial. Sex Transm Dis 2006; 33:445.
          </a>
         </li>
         <li class="breakAll">
          Expedited Partner Therapy. Centers for Disease Control and Prevention. April 2021. https://www.cdc.gov/std/ept/default.htm (Accessed on July 20, 2022).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Munson E, Reynoso A, Pass M, et al. Comprehensive Molecular Screening in a Cohort of Young Men Who Have Sex With Men and Transgender Women: Effect of Additive Rectal Specimen Source Collection and Analyte Testing. Sex Transm Dis 2020; 47:748.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Seña AC, Miller WC, Hobbs MM, et al. Trichomonas vaginalis infection in male sexual partners: Implications for diagnosis, treatment, and prevention. Clin Infect Dis 2007; 44:13.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Getaneh FW, Oliveira CR, Pathy S, Sheth SS. Disparities in adherence to retesting guidelines in women with Trichomonas vaginalis infection. Am J Obstet Gynecol 2023; 229:284.e1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lazenby GB, Thompson L, Powell AM, Soper DE. Unexpected High Rates of Persistent Trichomonas vaginalis Infection in a Retrospective Cohort of Treated Pregnant Women. Sex Transm Dis 2019; 46:2.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Craig-Kuhn MC, Granade C, Muzny CA, et al. Optimal Timing for Trichomonas vaginalis Test of Cure Using Nucleic Acid Amplification Testing. Sex Transm Dis 2019; 46:312.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kirkcaldy RD, Augostini P, Asbel LE, et al. Trichomonas vaginalis antimicrobial drug resistance in 6 US cities, STD Surveillance Network, 2009-2010. Emerg Infect Dis 2012; 18:939.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schwebke JR, Barrientes FJ. Prevalence of Trichomonas vaginalis isolates with resistance to metronidazole and tinidazole. Antimicrob Agents Chemother 2006; 50:4209.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dunne RL, Dunn LA, Upcroft P, et al. Drug resistance in the sexually transmitted protozoan Trichomonas vaginalis. Cell Res 2003; 13:239.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ghosh AP, Aycock C, Schwebke JR. In Vitro Study of the Susceptibility of Clinical Isolates of Trichomonas vaginalis to Metronidazole and Secnidazole. Antimicrob Agents Chemother 2018; 62.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sobel JD, Nagappan V, Nyirjesy P. Metronidazole-resistant vaginal trichomoniasis--an emerging problem. N Engl J Med 1999; 341:292.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sobel JD, Nyirjesy P, Brown W. Tinidazole therapy for metronidazole-resistant vaginal trichomoniasis. Clin Infect Dis 2001; 33:1341.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Subramanian C, Sobel JD. A case of high-level metronidazole-resistant trichomoniasis in pregnancy successfully treated. J Low Genit Tract Dis 2011; 15:248.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Alessio C, Nyirjesy P. Management of Resistant Trichomoniasis. Curr Infect Dis Rep 2019; 21:31.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Salas A, Hamill MM, Tuddenham S. Nitroimidazole Resistance in Trichomonas vaginalis Infection: A Teachable Moment. JAMA Intern Med 2019; 179:247.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Henien M, Nyirjesy P, Smith K. Metronidazole-Resistant Trichomoniasis: Beneficial Pharmacodynamic Relationship With High-Dose Oral Tinidazole and Vaginal Paromomycin Combination Therapy. Sex Transm Dis 2019; 46:e1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           McNeil CJ, Williamson JC, Muzny CA. Successful Treatment of Persistent 5-Nitroimidazole-Resistant Trichomoniasis With an Extended Course of Oral Secnidazole Plus Intravaginal Boric Acid. Sex Transm Dis 2023; 50:243.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nyirjesy P, Weitz MV, Gelone SP, Fekete T. Paromomycin for nitroimidazole-resistant trichomonosis. Lancet 1995; 346:1110.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Poppe WA. Nitroimidazole-resistant vaginal trichomoniasis treated with paromomycin. Eur J Obstet Gynecol Reprod Biol 2001; 96:119.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Van Gerwen OT, Camino AF, Bourla LN, et al. Management of Trichomoniasis in the Setting of 5-Nitroimidazole Hypersensitivity. Sex Transm Dis 2021; 48:e111.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Seyedroudbari S, McCloskey K, Muzny CA, et al. Multidrug-Resistant Trichomoniasis: Successful Treatment With 3 Months of Twice-Daily Intravaginal Boric Acid. Sex Transm Dis 2023; 50:452.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Edwards RJ, Parboo M, Edwards J, Boyce G. Trichomoniasis refractory to 5-nitroimidazole therapy in Trinidad. Trop Doct 2023; 53:143.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cudmore SL, Delgaty KL, Hayward-McClelland SF, et al. Treatment of infections caused by metronidazole-resistant Trichomonas vaginalis. Clin Microbiol Rev 2004; 17:783.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Seña AC, Bachmann LH, Hobbs MM. Persistent and recurrent Trichomonas vaginalis infections: epidemiology, treatment and management considerations. Expert Rev Anti Infect Ther 2014; 12:673.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dan M, Sobel JD. Failure of nitazoxanide to cure trichomoniasis in three women. Sex Transm Dis 2007; 34:813.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Helms DJ, Mosure DJ, Secor WE, Workowski KA. Management of trichomonas vaginalis in women with suspected metronidazole hypersensitivity. Am J Obstet Gynecol 2008; 198:370.e1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Biagi M, Slipke W, Smalley A, Tsaras G. Successful treatment of trichomoniasis with tinidazole following desensitization in a patient allergic to metronidazole. Int J STD AIDS 2021; 32:89.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kufel WD, Asiago-Reddy EA, Parsels KA, et al. Successful treatment with secnidazole for trichomoniasis in the setting of metronidazole hypersensitivity. Int J STD AIDS 2021; 32:1271.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           duBouchet L, Spence MR, Rein MF, et al. Multicenter comparison of clotrimazole vaginal tablets, oral metronidazole, and vaginal suppositories containing sulfanilamide, aminacrine hydrochloride, and allantoin in the treatment of symptomatic trichomoniasis. Sex Transm Dis 1997; 24:156.
          </a>
         </li>
         <li class="breakAll">
          Drugs and Lactation Database (LactMed). National Library of Medicine. 2006. https://www.ncbi.nlm.nih.gov/books/NBK501922/ (Accessed on July 22, 2022).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Passmore CM, McElnay JC, Rainey EA, D'Arcy PF. Metronidazole excretion in human milk and its effect on the suckling neonate. Br J Clin Pharmacol 1988; 26:45.
          </a>
         </li>
         <li class="breakAll">
          Drugs and Lactation Database (LactMed). Metronidazole. http://toxnet.nlm.nih.gov/cgi-bin/sis/search/f?./temp/~dNozos:1 (Accessed on February 13, 2013).
         </li>
         <li class="breakAll">
          Drugs and Lactation Database (LactMed). Bethesda (MD): National Library of Medicine (US); 2006-. https://www.ncbi.nlm.nih.gov/books/NBK501922/ (Accessed on October 13, 2022).
         </li>
         <li class="breakAll">
          SOLOSEC- secnidazole granule. US Food and Drug Administration (FDA) approved product information. Revised July, 2022. US National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed/ (Accessed on October 13, 2022).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kissinger P, Mena L, Levison J, et al. A randomized treatment trial: single versus 7-day dose of metronidazole for the treatment of Trichomonas vaginalis among HIV-infected women. J Acquir Immune Defic Syndr 2010; 55:565.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Adamski A, Clark RA, Mena L, et al. The influence of ART on the treatment of Trichomonas vaginalis among HIV-infected women. Clin Infect Dis 2014; 59:883.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gatski M, Martin DH, Levison J, et al. The influence of bacterial vaginosis on the response to Trichomonas vaginalis treatment among HIV-infected women. Sex Transm Infect 2011; 87:205.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 139046 Version 15.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34292926" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : Sexually Transmitted Infections Treatment Guidelines, 2021.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8435938" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : Trichomonas vaginalis: A reemerging pathogen
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35863010" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : In Vitro Effect of 5-Nitroimidazole Drugs against Trichomonas vaginalis Clinical Isolates.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/37005163" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Trichomoniasis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15489349" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Trichomoniasis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6997516" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Metronidazole for vaginal trichomoniasis. Seven-day vs single-dose regimens.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/627305" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Single-dose oral treatment of vaginal trichomoniasis with tinidazole and metronidazole.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12804391" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Interventions for treating trichomoniasis in women.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33768237" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Efficacy and Safety of Single Oral Dosing of Secnidazole for Trichomoniasis in Women: Results of a Phase 3, Randomized, Double-Blind, Placebo-Controlled, Delayed-Treatment Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8014510" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : A double-blind placebo-controlled trial of single-dose intravaginal versus single-dose oral metronidazole in the treatment of trichomonal vaginitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9524997" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : A pilot study of metronidazole vaginal gel versus oral metronidazole for the treatment of Trichomonas vaginalis vaginitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30297322" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Single-dose versus 7-day-dose metronidazole for the treatment of trichomoniasis in women: an open-label, randomised controlled trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27898571" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Single-dose compared with multidose metronidazole for the treatment of Trichomoniasis in women: A meta-analysis
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27898571" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Single-dose compared with multidose metronidazole for the treatment of Trichomoniasis in women: A meta-analysis
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34079999" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Epidemiology, Natural History, Diagnosis, and Treatment of Trichomonas vaginalis in Men.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3494323" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Urethral trichomoniasis in men.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3494323" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Urethral trichomoniasis in men.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31856123" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Vaginitis in Nonpregnant Patients: ACOG Practice Bulletin, Number 215.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/305809" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Metronidazole and tinidazole in a single large dose for treating urogenital infections with Trichomonas vaginalis in men.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29125715" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Two Phase 1, Open-Label, Single-Dose, Randomized, Crossover Studies to Assess the Pharmacokinetics, Safety, and Tolerability of Orally Administered Granules of Secnidazole (2 g) in Healthy Female Volunteers Under Different Administration Conditions.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29125715" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Two Phase 1, Open-Label, Single-Dose, Randomized, Crossover Studies to Assess the Pharmacokinetics, Safety, and Tolerability of Orally Administered Granules of Secnidazole (2 g) in Healthy Female Volunteers Under Different Administration Conditions.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29125715" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Two Phase 1, Open-Label, Single-Dose, Randomized, Crossover Studies to Assess the Pharmacokinetics, Safety, and Tolerability of Orally Administered Granules of Secnidazole (2 g) in Healthy Female Volunteers Under Different Administration Conditions.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35642509" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Secnidazole: a treatment for trichomoniasis in adolescents and adults.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7844427" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Trichomoniasis in non-gonococcic urethritis among male patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10676835" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Do ethanol and metronidazole interact to produce a disulfiram-like reaction?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25223673" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : [Is combining metronidazole and alcohol really hazardous?].
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31871085" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Fact versus Fiction: a Review of the Evidence behind Alcohol and Antibiotic Interactions.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31871076" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : A Population Pharmacokinetics and Pharmacodynamic Approach To Optimize Tazobactam Activity in Critically Ill Patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/4320226" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : Effect of metronidazole on liver alcohol dehydrogenase.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/4320226" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : Effect of metronidazole on liver alcohol dehydrogenase.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35701863" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : British Association for Sexual Health and HIV (BASHH) United Kingdom national guideline on the management of Trichomonas vaginalis 2021.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35015033" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : Diagnosis and Treatment of Sexually Transmitted Infections: A Review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35015033" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : Diagnosis and Treatment of Sexually Transmitted Infections: A Review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35153156" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : Secnidazole for Trichomoniasis in Women and Men.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24825333" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : Trichomonas vaginalis as a cause of perinatal morbidity: A systematic review and meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32282605" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : Trichomonas vaginalis in Pregnancy: Patterns and Predictors of Testing, Infection, and Treatment.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32282605" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : Trichomonas vaginalis in Pregnancy: Patterns and Predictors of Testing, Infection, and Treatment.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : Secnidazole, an approved single dose drug for bacterial vaginosis, does not cause reproductive toxicity in animals
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : Secnidazole, an approved single dose drug for bacterial vaginosis, does not cause reproductive toxicity in animals
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19361316" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : Treatment of trichomoniasis in pregnancy and preterm birth: An observational study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20429491" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : Treatment of trichomoniasis in pregnancy in sub-Saharan Africa does not appear to be associated with low birth weight or preterm birth.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16522393" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : The HPTN 024 Study: The efficacy of antibiotics to prevent chorioamnionitis and preterm birth.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15229009" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : Natural history of bacterial vaginosis and intermediate flora in pregnancy and effect of oral clindamycin.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9278206" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : Is metronidazole teratogenic? A meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16531939" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : Patient-delivered partner treatment for Trichomonas vaginalis infection: A randomized controlled trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16531939" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : Patient-delivered partner treatment for Trichomonas vaginalis infection: A randomized controlled trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33045163" id="rid46" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          47 : Comprehensive Molecular Screening in a Cohort of Young Men Who Have Sex With Men and Transgender Women: Effect of Additive Rectal Specimen Source Collection and Analyte Testing.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17143809" id="rid47" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          48 : Trichomonas vaginalis infection in male sexual partners: Implications for diagnosis, treatment, and prevention.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/37393012" id="rid48" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          49 : Disparities in adherence to retesting guidelines in women with Trichomonas vaginalis infection.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30067546" id="rid49" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          50 : Unexpected High Rates of Persistent Trichomonas vaginalis Infection in a Retrospective Cohort of Treated Pregnant Women.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30601374" id="rid50" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          51 : Optimal Timing for Trichomonas vaginalis Test of Cure Using Nucleic Acid Amplification Testing.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22608054" id="rid51" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          52 : Trichomonas vaginalis antimicrobial drug resistance in 6 US cities, STD Surveillance Network, 2009-2010.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17000740" id="rid52" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          53 : Prevalence of Trichomonas vaginalis isolates with resistance to metronidazole and tinidazole.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12974614" id="rid53" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          54 : Drug resistance in the sexually transmitted protozoan Trichomonas vaginalis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29439963" id="rid54" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          55 : In Vitro Study of the Susceptibility of Clinical Isolates of Trichomonas vaginalis to Metronidazole and Secnidazole.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10419394" id="rid55" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          56 : Metronidazole-resistant vaginal trichomoniasis--an emerging problem.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11565074" id="rid56" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          57 : Tinidazole therapy for metronidazole-resistant vaginal trichomoniasis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21558962" id="rid57" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          58 : A case of high-level metronidazole-resistant trichomoniasis in pregnancy successfully treated.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31388764" id="rid58" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          59 : Management of Resistant Trichomoniasis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30575848" id="rid59" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          60 : Nitroimidazole Resistance in Trichomonas vaginalis Infection: A Teachable Moment.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30106840" id="rid60" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          61 : Metronidazole-Resistant Trichomoniasis: Beneficial Pharmacodynamic Relationship With High-Dose Oral Tinidazole and Vaginal Paromomycin Combination Therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/36730040" id="rid61" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          62 : Successful Treatment of Persistent 5-Nitroimidazole-Resistant Trichomoniasis With an Extended Course of Oral Secnidazole Plus Intravaginal Boric Acid.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7564825" id="rid62" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          63 : Paromomycin for nitroimidazole-resistant trichomonosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11311775" id="rid63" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          64 : Nitroimidazole-resistant vaginal trichomoniasis treated with paromomycin.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33137011" id="rid64" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          65 : Management of Trichomoniasis in the Setting of 5-Nitroimidazole Hypersensitivity.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/36940199" id="rid65" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          66 : Multidrug-Resistant Trichomoniasis: Successful Treatment With 3 Months of Twice-Daily Intravaginal Boric Acid.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/36214266" id="rid66" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          67 : Trichomoniasis refractory to 5-nitroimidazole therapy in Trinidad.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15489348" id="rid67" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          68 : Treatment of infections caused by metronidazole-resistant Trichomonas vaginalis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24555561" id="rid68" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          69 : Persistent and recurrent Trichomonas vaginalis infections: epidemiology, treatment and management considerations.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17551415" id="rid69" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          70 : Failure of nitazoxanide to cure trichomoniasis in three women.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18221927" id="rid70" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          71 : Management of trichomonas vaginalis in women with suspected metronidazole hypersensitivity.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33121364" id="rid71" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          72 : Successful treatment of trichomoniasis with tinidazole following desensitization in a patient allergic to metronidazole.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34392726" id="rid72" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          73 : Successful treatment with secnidazole for trichomoniasis in the setting of metronidazole hypersensitivity.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9132982" id="rid73" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          74 : Multicenter comparison of clotrimazole vaginal tablets, oral metronidazole, and vaginal suppositories containing sulfanilamide, aminacrine hydrochloride, and allantoin in the treatment of symptomatic trichomoniasis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9132982" id="rid74" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          75 : Multicenter comparison of clotrimazole vaginal tablets, oral metronidazole, and vaginal suppositories containing sulfanilamide, aminacrine hydrochloride, and allantoin in the treatment of symptomatic trichomoniasis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3203060" id="rid75" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          76 : Metronidazole excretion in human milk and its effect on the suckling neonate.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3203060" id="rid76" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          77 : Metronidazole excretion in human milk and its effect on the suckling neonate.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3203060" id="rid77" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          78 : Metronidazole excretion in human milk and its effect on the suckling neonate.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3203060" id="rid78" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          79 : Metronidazole excretion in human milk and its effect on the suckling neonate.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21423852" id="rid79" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          80 : A randomized treatment trial: single versus 7-day dose of metronidazole for the treatment of Trichomonas vaginalis among HIV-infected women.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24917661" id="rid80" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          81 : The influence of ART on the treatment of Trichomonas vaginalis among HIV-infected women.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21278401" id="rid81" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          82 : The influence of bacterial vaginosis on the response to Trichomonas vaginalis treatment among HIV-infected women.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
